玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察

doi:10.6040/j.issn.1673-3770.0.2017.033

摘要/Abstract

摘要： 目的研究玻璃体腔注射雷珠单抗(IVR)治疗有临床意义的黄斑水肿(CSME)及非临床意义的黄斑水肿(NCSME)患者的临床效果。方法将糖尿病黄斑水肿(DME)的患者77例,分为CSME组及NCSME组,行IVR治疗,比较治疗前后患者的最佳矫正视力(BCVA)和黄斑水肿最高高度。结果两组治疗1个月后,BCVA较治疗前差异均有统计学意义(P<0.05)。两组间比较,治疗前后各时间点黄斑水肿最高高度差异均无统计学意义(P>0.05)。结论 CSME及NCSME患者行IVR治疗后黄斑水肿高度降低,但黄斑水肿高度不能完全反映患者视力情况。

关键词: 雷珠单抗, 糖尿病性黄斑水肿, 最高高度, 最佳矫正视力

Abstract: Objective To explore the clinical efficacy of clinically significant macular edema(CSME)and non-clinically significant macular edema(NCSME)treated with Ranibizumab intravitreal injection. Methods A total of 77 BRVO-ME cases were divided into 2 groups: CSME group(n=51)and NCSME group(n=26). The two groups received Ranibizumab intravitreal injection. Best corrected visual acuity(BCVA)and highest thickness of macular edema of the two groups were observed. Results One months after treatment, BCVA of the two groups were improved(P<0.05). No significant difference between two groups was found in the highest thickness of macular edema(P>0.05). Conclusion Ranibizumab intravitreal injection can improve visual acuity and reduce the highest thickness of macular edema in patients with CSME and NCSME. The highest thickness of macular edema can not completely reflect the visual acuity.

Key words: Best corrected visual acuity, Highest thickness, Diabetic macular edema, Ranibizumab

中图分类号:

R774

靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.

参考文献

[1] 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014)[J]. 中华眼科杂志,2014,50(11):851-865.
[2] Klein R, Knudtson MD, Lee KE, et al. The wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes[J]. Ophthalmology, 2009, 116(3):497-503.
[3] LHeveder R, Nolan T. International diabetes federation[J]. Diabetes Research & Clinical Practice, 2013, 101(3):349-351.
[4] 金慧昳,刘海芸,刘堃,等. 糖尿病黄斑水肿患者黄斑区形态与视功能的关系[J]. 中华医学杂志, 2013, 93(7):524-527. JIN Huiyi, LIU Haiyun, LIU Kun, et al. Relationship between macular morphology and visual function in diabetic macular edema[J]. Natl Med J Chin, 2013, 93(7):524-527.
[5] 董蒙,陈松. 雷珠单抗治疗糖尿病黄斑水肿研究进展[J]. 中国实用眼科杂志,2014,32(6):686-689.
[6] Azad SV, Salman A, Mahajan D, et al. Comparative evaluation between Ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion[J]. Mid East Afr J Ophthalmol, 2014, 21(4):296-301.
[7] Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents[J]. Br J Ophthalmol, 2011, 95(8):1111-1114.
[8] Lyall DAM, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors and outcomes[J]. Eye, 2012, 26(12):1517-1526.
[9] Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature[J]. Eye, 2013, 27(7):787-94.
[10] Mori F, Hikichi T, Takahashi J, et al. Dysfunction of active transport of blood-retinal barrier in patients with clinically significant macular edema in type 2 diabetes[J]. Diabetes Care, 2002, 25(7):1248-1249.
[11] Emanuele N, Moritz T, Klein R, et al. Ethnicity,race,and clinically significant macular edema in the Veterans Affairs Diabetes Trial(VADT)[J]. Diab Res Clin Pract, 2009, 86(2):104-110.
[12] Jew OM, Peyman M, Chen TC, et al. Risk factors for clinically significant macular edema in a multi-ethnics population with type 2 diabetes[J]. Int J Ophthalmol, 2012, 5(4):499-504.
[13] Ribeiro L, Nunes S, Cunhavaz J. Microaneurysm turnover in the macula is a biomarker for development of clinically significant macular edema in type 2 diabetes[J]. Current Biomarker Findings, 2013, 3:11-15.
[14] Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(4):825-833.
[15] Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside[J]. Ophthalmology, 2016, 123(10):S78-S88.
[16] Kiss CG, Barisani-Asenbauer T, Maca S, et al. Reading performance of patients with uveitis-associated cystoid macular edema[J]. Am J Ophthalmol, 2006, 142(142):620-624.
[17] Network DRC. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema[J]. Ophthalmology, 2007, 114(3):525-536.
[18] 韩月圣, 魏文斌. Ranibizumab玻璃体腔注射后糖尿病黄斑水肿患者中心视网膜厚度相对变化与视力预后的关系[J].中华实验眼科杂志,2016,34(1):78-84. HAN Yuesheng, WEI Wenbin. The relationship between central retinal thickness relative change and visual prognosis in diabetic macular edema patients following intravitreal injection of ranibizumab[J]. Chin J Exper Ophthalmol, 2016, 34(1):78-84.
[19] Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study[J]. Ophthalmology, 2009, 116(3):461-461.
[20] Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4):789-801.
[21] 刘玉华,高玲. 糖尿病视网膜病变治疗研究现状、问题与展望[J]. 中华眼底病杂志,2016,32(2):206-210. LIU Yuhua, GAO Ling. The status, problem and progress of diabetic retinopathy treatment[J]. Chin J Ocular Fundus Dis, 2016, 32(2):206-210.
[22] 许迅,郑颖. 重视对糖尿病黄斑水肿的治疗[J].中华眼底病杂志,2016,32(2):119-121. XU Xun, ZHENG Ying. Focusing on the treatment of diabetic macular edema[J]. Chinese Journal of Ocular Fundus Diseases, 2016, 32(2):119-121.
[23] 汪枫桦,张鹏飞,孙晓东. 抗血管内皮生长因子治疗不应忽视激光的作用[J]. 中华眼科杂志,2015,51(12):885-887. WANG Fenghua, ZHANG Pengfei, SUN Xiaodong. The role of laser photocoagulation in the anti-vascular endothelial growth factor therapy era[J]. Chin J Ophthalmol, 2015, 51(12):885-887.

相关文章 11

[1]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[2]	严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[3]	赵露,谢国丽,王艳玲. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者眼血流动力学的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 101-104.
[4]	邵娜,张晗. 糖尿病患者行白内障超声乳化术后视力及眼底的变化[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 83-87.
[5]	柴雪荣, 张士玺, 陶钰, 申家泉. 玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的效果评价[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 72-75.
[6]	龚斌, 范传峰, 王玉. 抗VEGF药物(雷珠单抗)治疗不同病程湿性年龄相关性黄斑变性62例[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 58-61.
[7]	张爱慧1，朱灵1，张金枝1，张伟2. 白内障超声乳化人工晶体植入术与年龄相关性黄斑变性的相关性研究[J]. 山东大学耳鼻喉眼学报, 2013, 27(5): 77-83.
[8]	谢丽综述，魏伟审校. 糖尿病性黄斑水肿的治疗进展[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 81-85.
[9]	王永波，石安娜，石浔，金昱，刘维锋. 视网膜静脉阻塞患者光感受器细胞层与最佳视力之间的关系[J]. 山东大学耳鼻喉眼学报, 2013, 27(1): 78-80.
[10]	卢爱东,刘晓玲,高洁,陈芳,梁仲琪 . 曲安奈德联合微脉冲激光治疗糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 366-368 .
[11]	卢爱东,陈芳,梁仲琪 . 玻璃体腔内注射曲安奈德治疗严重糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2008, 22(1): 17-18 .

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed